Fyrwald J Erik 4

What Happened J. Erik Fyrwald, a director of Eli Lilly & Co. (LLY), received an award of 10.026 shares (transaction code A) on 2026-03-16. The filing reports a per-share valuation of $989.12, for a total reported value of $9,917. This was a grant of director compensation that the reporting person elected to defer rather than take as cash.

Key Details

• Transaction date: 2026-03-16; Form 4 filed: 2026-03-17 (timely).
• Transaction type/code: Award/Grant (A).
• Shares acquired: 10.026; reported price/value: $989.12 per share; total ~$9,917.
• Shares owned after transaction: Not specified in this Form 4.
• Footnote: At the reporting person's election, the shares were deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares upon the reporting person's separation from service.
• No indication of a 10b5-1 plan, sale, or tax-withholding action in this filing.

Context This was a routine director compensation award deferred into stock units, not an open-market purchase or sale. Deferred awards like this are common for directors and are typically part of standard compensation — they do not necessarily indicate a change in the director's view on the company’s stock.